WS Investor
12 Aug 2026, 15:49
Thermo Fisher Completes $1.08 Billion Sale of Microbiology Business to Astorg
Thermo Fisher Scientific (NYSE: TMO) has completed the sale of its microbiology business to private equity firm Astorg for approximately $1.075 billion.
The consideration consists primarily of cash along with a $50 million seller note. The divested business generated $645 million in revenue in 2025 and previously operated within Thermo Fisher’s Specialty Diagnostics segment.
The microbiology unit provides antimicrobial susceptibility testing and culture media solutions used in clinical, pharmaceutical and food-safety testing.
The transaction represents a portfolio optimization move for Thermo Fisher, allowing the company to monetize a non-core diagnostics operation while concentrating resources on its broader life sciences, analytical technologies, laboratory products and pharmaceutical services businesses.
With more than $45 billion in annual revenue, the divested operation represents a relatively small portion of Thermo Fisher’s overall business. The $1.075 billion transaction values the microbiology unit at approximately 1.7 times its 2025 revenue.
Thermo Fisher Scientific (NYSE: TMO) has completed the sale of its microbiology business to private equity firm Astorg for approximately $1.075 billion.
The consideration consists primarily of cash along with a $50 million seller note. The divested business generated $645 million in revenue in 2025 and previously operated within Thermo Fisher’s Specialty Diagnostics segment.
The microbiology unit provides antimicrobial susceptibility testing and culture media solutions used in clinical, pharmaceutical and food-safety testing.
The transaction represents a portfolio optimization move for Thermo Fisher, allowing the company to monetize a non-core diagnostics operation while concentrating resources on its broader life sciences, analytical technologies, laboratory products and pharmaceutical services businesses.
With more than $45 billion in annual revenue, the divested operation represents a relatively small portion of Thermo Fisher’s overall business. The $1.075 billion transaction values the microbiology unit at approximately 1.7 times its 2025 revenue.
